Ernexa Therapeutics to Present at Oxford Global’s Cell 2025

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) will present at Oxford Global's Cell 2025 in London on November 11–12, 2025. Sanjeev Luther, President and CEO, will give an oral talk titled "Preparing Cell Therapies for Clinics" on Nov 12 at 12:50 PM GMT and join a panel on Nov 12 at 4:35 PM GMT addressing development, funding, and regulatory strategies for its engineered induced mesenchymal stem cell (iMSC) platform. Presentations focus on trial design, early regulatory engagement, partnerships, and scalable design to translate cell therapies into clinical practice.

News Market Reaction

-5.39%

1 alert

-5.39% News Effect

-$747K Valuation Impact

$13M Market Cap

1K Volume

On the day this news was published, ERNA declined 5.39%, reflecting a notable negative market reaction. This price movement removed approximately $747K from the company's valuation, bringing the market cap to $13M at that time.

Data tracked by StockTitan Argus on the day of publication.

Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussion

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will present at Cell 2025, Oxford Global’s premier event, being held on November 11 and 12, 2025 in London, UK.

Details of the presentations are as follows:

Title: Preparing Cell Therapies for Clinics
Presenter: Sanjeev Luther, President and CEO of Ernexa Therapeutics
Session: Innovation and Collaboration Programme
Date and Time: Wednesday, November 12^th at 12:50 PM GMT
Location: Conference Room 4: Muscadet, Novotel London West, London, UK

Panel Presentation: Challenges of Navigating Development & How To Get To The Clinic
Panel Participants: Sanjeev Luther, President and CEO of Ernexa Therapeutics, and Lucy Williams, Partner, European & UK Patent Attorney, J A Kemp
Session: Cell Culture & Bioprocessing
Track: Downstream Bioprocessing & Innovation Collaboration
Date and Time: Wednesday, November 12^th at 4:35 PM GMT
Location: Conference Room 2: Bourgogne, Novotel London West, London, UK

The presentations will include insights on how the industry can more effectively translate cell therapy innovations into clinical success. In Luther’s first presentation, “Preparing Cell Therapies for Clinics,” he will explore how smart trial design and early regulatory engagement can accelerate clinical progress without compromising safety or rigor – principles he emphasizes in fast-tracking cell therapy development.

Later, in the panel discussion, Luther will address the interplay of funding, innovation, and regulatory strategy in advancing Ernexa’s engineered induced mesenchymal stem cell (iMSC) platform. Drawing on his experiences, he will highlight how early partnerships, scalable design, and coordinated engagement with regulators can drive the next generation of synthetic, off-the-shelf therapies from bench to bedside.     

Cell 2025, Oxford Global’s flagship event, serves as the ultimate meeting place for bioprocessing and advanced therapy professionals. This event brings together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell and gene therapy value chain. In line with current industry trends, the event explores the transformative power of AI and machine learning in manufacturing, driving innovation and efficiency in advanced therapies. For more information, please visit the event website.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Ernexa Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Ernexa Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

When will Ernexa Therapeutics (ERNA) present at Cell 2025 in London?

Ernexa will present on November 12, 2025 with sessions at 12:50 PM GMT and 4:35 PM GMT.

What topics will Sanjeev Luther cover in the ERNA presentation on Nov 12, 2025?

He will discuss "Preparing Cell Therapies for Clinics", focusing on smart trial design and early regulatory engagement.

What will the ERNA panel at Cell 2025 address for ERNA (ERNA) investors?

The panel will address funding, innovation, regulatory strategy, and steps to advance Ernexa’s iMSC platform toward the clinic.

Where are Ernexa's Cell 2025 presentations being held on Nov 12, 2025?

Both sessions are at Novotel London West: the talk in Conference Room 4: Muscadet and the panel in Conference Room 2: Bourgogne.

Will Ernexa discuss regulatory strategy and partnerships at Cell 2025 (ERNA)?

Yes; presentations emphasize early regulatory engagement and early partnerships as ways to accelerate clinical progress.

How do Ernexa’s Cell 2025 presentations relate to its engineered iMSC platform?

Ernexa will highlight how scalable design and coordinated regulatory steps can help translate its engineered iMSC therapies from bench to clinic.